中华移植杂志（电子版）
中華移植雜誌（電子版）
중화이식잡지（전자판）
Chinese Journal of Transplantation(Electronic Version)
2011年
3期
45-49
,共5页
器官移植%免疫功能%CD4+T淋巴细胞%腺苷三磷酸%ImmuKnow技术%感染%排斥反应%免疫监测
器官移植%免疫功能%CD4+T淋巴細胞%腺苷三燐痠%ImmuKnow技術%感染%排斥反應%免疫鑑測
기관이식%면역공능%CD4+T림파세포%선감삼린산%ImmuKnow기술%감염%배척반응%면역감측
Organ transplantation%Immune function%CD4+ T lymphocytes%Adenosine triphosphate%ImmuKnow technology%Infection%Rejection%Immune monitoring
科学监测器官移植受者免疫水平是进一步提供个体化免疫抑制治疗、提高受者长期存活率的关键.2002年通过美国食品药品管理局认证的CD4+T细胞内腺苷三磷酸含量检测技术(ImmuKnow技术)是目前最为便捷且成熟的评估免疫抑制人群细胞免疫功能状态的新途径.大量临床研究证实ImmuKnow检测结果与肝、肾、心脏、肠、胰腺移植受者的排斥反应事件、感染事件或临床稳定状态之间存在相关性.移植受者理想的ImmuKnow检测结果参考范围亦逐步明确.在实体器官移植中,ImmuKnow技术显示了预测感染和排斥反应风险的巨大应用前景.已有多个临床中心尝试依据ImmuKnow检测结果调整个体免疫抑制治疗方案并取得了初步的成果,其临床的推广应用尚需参照更多前瞻性研究、成本效益分析结果.
科學鑑測器官移植受者免疫水平是進一步提供箇體化免疫抑製治療、提高受者長期存活率的關鍵.2002年通過美國食品藥品管理跼認證的CD4+T細胞內腺苷三燐痠含量檢測技術(ImmuKnow技術)是目前最為便捷且成熟的評估免疫抑製人群細胞免疫功能狀態的新途徑.大量臨床研究證實ImmuKnow檢測結果與肝、腎、心髒、腸、胰腺移植受者的排斥反應事件、感染事件或臨床穩定狀態之間存在相關性.移植受者理想的ImmuKnow檢測結果參攷範圍亦逐步明確.在實體器官移植中,ImmuKnow技術顯示瞭預測感染和排斥反應風險的巨大應用前景.已有多箇臨床中心嘗試依據ImmuKnow檢測結果調整箇體免疫抑製治療方案併取得瞭初步的成果,其臨床的推廣應用尚需參照更多前瞻性研究、成本效益分析結果.
과학감측기관이식수자면역수평시진일보제공개체화면역억제치료、제고수자장기존활솔적관건.2002년통과미국식품약품관리국인증적CD4+T세포내선감삼린산함량검측기술(ImmuKnow기술)시목전최위편첩차성숙적평고면역억제인군세포면역공능상태적신도경.대량림상연구증실ImmuKnow검측결과여간、신、심장、장、이선이식수자적배척반응사건、감염사건혹림상은정상태지간존재상관성.이식수자이상적ImmuKnow검측결과삼고범위역축보명학.재실체기관이식중,ImmuKnow기술현시료예측감염화배척반응풍험적거대응용전경.이유다개림상중심상시의거ImmuKnow검측결과조정개체면역억제치료방안병취득료초보적성과,기림상적추엄응용상수삼조경다전첨성연구、성본효익분석결과.
A scientific monitory method of organ transplant recipients' immune function is the key of applying individualized immuppresuppresive therapy and improving long-term survival.Immune function assay detecting CD4 +T lymphocyte adenosine triphosphate level (ImmuKnow technology),approved by the U.S.Food Drug Administration in 2002,so far,is the most convenient and mature method of cellular immune function assessment in the group of immunosuppressed people.A large number of clinical studies proved the correlations between the test results and rejection events,infections or clinical stability of liver,kidney,heart,intestines,and pancreas transplant recipients.The ideal ImmuKnow reference range has gradually been clear.In solid organ transplantation,the ImmuKnow technology showed great prospects of application in predicting the risk of infection or rejection.Several clinical centers have tried to adjust the individual immunosuppressive therapy based on the results of ImmuKnow tests and have gained initial success.The clinical value of the ImmuKnow technology has been confirmed in the initial studies,however,its further clinical application needs more evidence from clinical trials such as prospective studies and cost benefit analysis.
